Evidence map›Paper›PMID 41419904›Full record

ArticleBMC health services research2025

Costing analysis of a Queensland community corrections hepatitis C screening program.

Kelly Maynard, Farah Houdroge, Rachael Thompson, Anna L Hawkes, Alisa Pedrana, Jacqueline A Richmond, Nick Scott

Abstract read
In one paragraph

Article in BMC health services research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kelly MaynardDisease Elimination Program, Burnet Institute, 85 Commercial Rd, Melbourne, Victoria, 3004, Australia.
Farah HoudrogeDisease Elimination Program, Burnet Institute, 85 Commercial Rd, Melbourne, Victoria, 3004, Australia.
Rachael ThompsonHepatitis Queensland Inc., 12 Birubi St., Coorparoo, Queensland, 4151, Australia.
Anna L HawkesHepatitis Queensland Inc., 12 Birubi St., Coorparoo, Queensland, 4151, Australia.
Alisa PedranaDisease Elimination Program, Burnet Institute, 85 Commercial Rd, Melbourne, Victoria, 3004, Australia.
Jacqueline A RichmondDisease Elimination Program, Burnet Institute, 85 Commercial Rd, Melbourne, Victoria, 3004, Australia.
Nick ScottDisease Elimination Program, Burnet Institute, 85 Commercial Rd, Melbourne, Victoria, 3004, Australia. nick.scott@burnet.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeople involved with the criminal justice system typically have lower healthcare engagement and higher risk of hepatitis C virus (HCV) infection than the general population. Interventions run at community corrections centres have the potential to diagnose and treat previously unreached populations. This study aimed to estimate the cost per treatment initiation and cost per cure through HCV programs at community corrections centres.

methodsData were obtained over the period of July 2022 to July 2023 from screening clinics run by Hepatitis Queensland in four community corrections centres located in Brisbane, Australia. All non-drugcosts (presented in 2023 A$ without discounting) were included from the perspective of the clinics, including staff salaries, general practitioner (GP) fees, logistics, medical testing, incentives and overhead costs. Costs of follow up instances were estimated from total nurse follow-up time per clinic.

resultsThe total non-drug cost accumulated over 33 clinics in the 13-month study period was $159,982. Among the 185 participants, 23 tested RNA positive (12%). At the end of the study period 8 participants had achieved sustained virologic response (SVR) and 6 were still on treatment. This resulted in a cost per cure of $19,998 or $11,427 per patient initiated on treatment. If GP costs were excluded (i.e. paid by Medicare and not the clinic) the cost per cure and cost per treatment initiation were $12,843 and $7,339 respectively.

conclusionsAs overall prevalence decreases and case finding becomes a greater challenge, providing HCV testing and treatment through community correctional centres may be a cost-effective way of reaching people living with HCV not engaged with healthcare.

Indexed as

Hepatitis CMass ScreeningPrisonsAdultAntiviral AgentsCosts and Cost AnalysisFemaleHumansMaleMiddle AgedQueenslandAntiviral AgentsCommunity correctionsCostEconomic analysisHepatitis CTesting

Identifiers

PMID41419904
PMCPMC12717760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.